Back to News
Dec 15, 2025 12:40 PM

Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst

Pfizer Inc. (NYSE:PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions seen in 2025.

According to BofA, Pfizer's outlook is likely to remain flattish, supported primarily by disciplined expense management rather than top-line acceleration.

Analyst Jason Gerberry reiterated a Neutral rating on the stock and trimmed his price forecast to $28 from $29, reflecting a valuation based on 9.5 times estimated fiscal 2027 earnings, compared with a prior 9 times fiscal 2026 estimate.

Also Read: FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back

Loss Of Exclusivity Continues To Weigh On Valuation

Looking ahead to 2026, BofA said it sees limited catalysts for a meaningful re-rating as Pfizer continues to navigate a multi-year loss of exclusivity cycle that is expected to ...